Reported Earlier, HUTCHMED Publishes Phase III Sovleplenib Results, 48.4% Response Rate In ITP Patients Versus 0% In Placebo Group

Benzinga ·  Jun 17 15:04

— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo —

— Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior lines of therapies or prior TPO/TPO-RA1 exposure —

— Data supported regulatory submission in China accepted in January 2024 —

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment